Alcester, Warwickshire, UK, 01 June 2020: Quanta Dialysis Technologies Ltd (“Quanta” or the “Company”), a British research firm in medical technology , today announces that it has proudly sponsored the ongoing NHS COVID-19 emergency dialysis response by supplying its next-generation SC+ haemodialysis system to select NHS trusts in the UK. Quanta supplied an initial batch of equipment and trained staff to the Royal Berkshire NHS Foundation Trust, where SC+ was used in intensive care unit ( ICU) treatment of COVID-19 patients in need of life-sustaining dialysis therapy. Cambridge University Hospitals NHS Foundation Trust, Manchester University NHS Foundation Trust and Oxford University Hospitals NHS Foundation Trust have all supplied facilities and provided instruction.

A concomitant acute kidney failure can affect up to a third of all patients diagnosed with COVID-19, requiring life-long renal replacement therapy such as haemodialysis. Quanta ‘s workers have been working relentlessly around the clock to meet the urgent NHS demand for additional dialysis power, while Quanta ‘s main suppliers are also working on additional changes to improve both machine and consumables production. SC+ was planned for ease of use and Quanta trained more than 70 ICU nurses as part of this contract, all of whom completed their training in less than six hours. Quanta also offers critical protective equipment for NHS, such as, Semi-reusable surgical mask adapters and face shield cases, made using 3D-printers from the service.

Emma Vaux, Royal Berkshire NHS Foundation Trust Consultant Nephrologist, added: “We are excited to be the first hospital in the UK to use the new SC+ system. During a time when there is an ongoing national shortage of dialysis machines, and a increasing need to treat more patients with COVID-19-related renal problems, Quanta was able to supply SC+ devices within days. SC+ has been implemented securely and, thanks to its ease of use, Quanta has been able to offer training in less than six hours , allowing our ICU nurses to treat those patients who need it most easily, effectively and efficiently. We look forward to seeing these apps used in home settings for our patient in the long term. Sandip Mitra, Manchester University NHS Foundation Trust Consultant Nephrologist, said:

“During the COVID-19 pandemic, the launch of the new SC+ system had a major effect in helping critically ill patients suffering kidney failures. The SC+ system, as a flexible and portable dialysis unit, provides a wide variety of renal replacement therapy options for ICUs, dialysis clinics, and home owned patients. In the near term it will also be crucial to rapidly increase the use of home haemodialysis to reduce the risk of COVID-19 in dialysis patients.

John E. Milad, Chief Executive Officer, said: “Everyone at Quanta is pulling out all the stops during this critical time to support the patients with NHS and kidney failure and I would like to thank our team for making this happen so fast. I ‘m proud to see the difference we can make with our small, easy and scalable haemodialysis program, SC+, by giving patients in urgent need flexible treatment options.

For more information about Quanta, please contact:


John E. Milad,
Chief Executive Officer

T: +44 (0)1789 400043
E: [email protected]

Consilium Strategic Communications
Amber Fennell / Matthew Neal / Lindsey Neville
T: +44 (0)203 709 5708
E: [email protected]

About Quanta and SC+

Quanta, headquartered in the UK’s Midlands, is a technology-enabled supplier of creative goods and services in the dialysis. Quanta strives to boost dialysis patients ‘ lives by beautifully designed solutions. The lead product SC+ is a compact, quick and flexible haemodialysis system designed to provide greater independence and versatility in providing life-sustaining dialysis treatments — making the therapy accessible to a wide range of patients in a number of settings, from ICU to home.

SC+ was successfully piloted with the NHS as a CE marked medical tool, demonstrating clinical effectiveness and efficiency consistent with conventional care regimens used in-centre. Behind SC+, the revolutionary and proprietary technology is based on a design innovation that allows all dialysate fluid management to be done on a compact , lightweight, disposable surface. SC+’s unobtrusive, simple-to-use, and digitally linked interface is designed to enable more patients with self-care and home dialysis to take charge of their lives. Meanwhile, SC+ supports dialysis delivery as a portable, compact and versatile device across a range of care settings and prescriptions for therapy.